Evidence map›Paper›PMID 26231084›Full record

ArticleJournal of molecular and cellular cardiology2015

Comparative effects of urocortins and stresscopin on cardiac myocyte contractility.

Catherine A Makarewich, Constantine D Troupes, Sarah M Schumacher, Polina Gross, Walter J Koch, David L Crandall, Steven R Houser

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular and cellular cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Catherine A MakarewichCardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA; Department of Physiology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Constantine D TroupesCardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA; Department of Physiology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Sarah M SchumacherCenter for Translational Research, Temple University School of Medicine, Philadelphia, PA 19140, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Polina GrossCardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA; Department of Physiology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Walter J KochCenter for Translational Research, Temple University School of Medicine, Philadelphia, PA 19140, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
David L CrandallJanssen Research & Development, LLC, Spring House, PA 19044, USA.
Steven R HouserCardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA; Department of Physiology, Temple University School of Medicine, Philadelphia, PA 19140, USA. Electronic address: srhouser@temple.edu.
Temple University · USJanssen (United States) · US

Funding

PKC alpha as a translational target in Heart FailureP01HL108806 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI RABINOWITZ, JOSEPH E · 2012 to 2016
$11.3M
Calcium and Cardiac Regeneration after Myocardial InfarctionR01HL033921 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI HOUSER, STEVEN R · 1985 to 2017
$5.6M
CONTRACTILITY OF FAILING AND RECOVERING HUMAN MYOCYTESR01HL061495 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI HOUSER, STEVEN R · 1998 to 2006
$3.1M
NHLBI NIH HHS P01 HL108806NHLBI NIH HHS R01 HL033921NHLBI NIH HHS R01 HL061495
6 · The paper itself

Abstract

rationaleThere is a current need for the development of new therapies for patients with heart failure.

objectiveWe test the effects of members of the corticotropin-releasing factor (CRF) family of peptides on myocyte contractility to validate them as potential heart failure therapeutics. METHODS AND

resultsAdult feline left ventricular myocytes (AFMs) were isolated and contractility was assessed in the presence and absence of CRF peptides Urocortin 2 (UCN2), Urocortin 3 (UCN3), Stresscopin (SCP), and the β-adrenergic agonist isoproterenol (Iso). An increase in fractional shortening and peak Ca(2+) transient amplitude was seen in the presence of all CRF peptides. A decrease in Ca(2+) decay rate (Tau) was also observed at all concentrations tested. cAMP generation was measured by ELISA in isolated AFMs in response to the CRF peptides and Iso and significant production was seen at all concentrations and time points tested.

conclusionsThe CRF family of peptides effectively increases cardiac contractility and should be evaluated as potential novel therapeutics for heart failure patients.

Indexed as

AnimalsCatsCorticotropin-Releasing HormoneHeart FailureHeart VentriclesHumansMyocardial ContractionMyocytes, CardiacUrocortinsCorticotropin-Releasing HormoneUrocortinsCalciumContractilityCorticotropin-releasing factorHeart failureUrocortin

Identifiers

PMID26231084
PMCPMC4558371
OpenAlexW1780980585

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.